Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Am J Hematol. 2014 Apr;89(4):404-9. doi: 10.1002/ajh.23656. Epub 2014 Feb 21.
Bronchiolitis obliterans syndrome (BOS) is a form of chronic graft vs. host disease (cGVHD) and a highly morbid pulmonary complication after allogeneic hematopoietic stem cell transplantation (HSCT). We assessed the prevalence and risk factors for BOS and cGVHD in a cohort of HSCT recipients, including those who received reduced intensity conditioning (RIC) HSCT. Between January 1, 2000 and June 30, 2010, all patients who underwent allogeneic HSCT at our institution (n = 1854) were retrospectively screened for the development of BOS by PFT criteria. We matched the BOS cases with two groups of control patients: (1) patients who had concurrent cGVHD without BOS and (2) those who developed neither cGVHD nor BOS. Comparisons between BOS patients and controls were conducted using t-test or Fisher's exact tests. Multivariate regression analysis was performed to examine factors associated with BOS diagnosis. All statistical analyses were performed using SAS 9.2. We identified 89 patients (4.8%) meeting diagnostic criteria for BOS at a median time of 491 days (range: 48-2067) after HSCT. Eighty-six (97%) of our BOS cohort had extra-pulmonary cGVHD. In multivariate analysis compared to patients without cGVHD, patients who received busulfan-based conditioning, had unrelated donors, and had female donors were significantly more likely to develop BOS, while ATG administration was associated with a lower risk of BOS. Our novel results suggest that busulfan conditioning, even in RIC transplantation, could be an important risk factor for BOS and cGVHD.
闭塞性细支气管炎综合征(BOS)是一种慢性移植物抗宿主病(cGVHD),也是异基因造血干细胞移植(HSCT)后一种高度致命的肺部并发症。我们评估了一组 HSCT 受者中 BOS 和 cGVHD 的患病率和危险因素,包括接受强度降低的 conditioning(RIC)HSCT 的受者。2000 年 1 月 1 日至 2010 年 6 月 30 日期间,我们机构所有接受异基因 HSCT 的患者(n = 1854)均通过 PFT 标准回顾性筛查 BOS 的发生。我们将 BOS 病例与两组对照患者进行匹配:(1)同时患有 cGVHD 但无 BOS 的患者,(2)既未发生 cGVHD 也未发生 BOS 的患者。使用 t 检验或 Fisher 确切检验比较 BOS 患者与对照组患者。采用多变量回归分析检查与 BOS 诊断相关的因素。所有统计分析均使用 SAS 9.2 进行。我们在 HSCT 后中位数时间为 491 天(范围:48-2067)时,确定了 89 例符合 BOS 诊断标准的患者(4.8%)。我们 BOS 队列的 86(97%)例患者有肺外 cGVHD。与无 cGVHD 的患者相比,多变量分析显示接受以白消安为基础的 conditioning、无关供体和女性供体的患者发生 BOS 的可能性明显更高,而 ATG 给药与 BOS 的风险降低相关。我们的新结果表明,即使在 RIC 移植中,白消安 conditioning 也可能是 BOS 和 cGVHD 的重要危险因素。